 Connection
Brad Constant to Retrospective Studies
This is a "connection" page, showing publications Brad Constant has written about Retrospective Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.246 |
|
|
|
-
Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2022 12 01; 75(6):724-730.
Score: 0.059
-
Constant BD, de Zoeten EF, Weinman JP, Albenberg L, Scott FI. Early Anti-Tumor-Necrosis-Factor Therapy for Crohn's Disease-Related Abdominal Abscesses and Phlegmon in Children. Dig Dis Sci. 2023 03; 68(3):877-888.
Score: 0.059
-
Constant BD, de Zoeten EF, Stahl MG, Vajravelu RK, Lewis JD, Fennimore B, Gerich ME, Scott FI. Delays Related to Prior Authorization in Inflammatory Bowel Disease. Pediatrics. 2022 03 01; 149(3).
Score: 0.057
-
Constant BD, Khushal S, Jiang J, Bost JE, Chaisson E, Conklin LS. Early Inflammatory Markers are Associated With Inadequate Post-Induction Infliximab Trough in Pediatric Crohn's Disease. J Pediatr Gastroenterol Nutr. 2021 03 01; 72(3):410-416.
Score: 0.053
-
Mitchel EB, Dolinger MT, Constant B, Wang Z, Guisado D, Gao M, Fusillo S, Baldassano RN, Kelsen J, Dubinsky M, Huang J, Albenberg L. Ustekinumab is safe and effective in pediatric patients with Crohn's disease. J Pediatr Gastroenterol Nutr. 2025 Apr; 80(4):653-663.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|